BioCryst to Receive $4 Million Milestone Payment in Connection With Initiation of Phase III Studies of Oral Neuraminidase Inhibitor RWJ-270201 (BCX-1812) in North America and Europe.
Business Wire › February 08, 2000
Linked as:
Extract
BioCryst to Receive $4 Million Milestone Payment in Connection With Initiation of Phase III Studies of Oral Neuraminidase Inhibitor RWJ-270201 (BCX-1812) in North America and Europe.
Business Editors, Health/Medical Writers
BIRMINGHAM, Ala.--(BW HealthWire)--Feb. 8, 2000 Studies Initiated by The R.W. Johnson Pharmaceutical Research Institute BioCryst Pharmaceuticals, Inc. (Nasdaq NM: BCRX) t...See the full content of this document
Sponsored links
